Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.
Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.
Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.
Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.
Alvotech (NASDAQ: ALVO) filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission on March 30, 2026. The filing incorporates parts of the Alvotech Annual Report 2025 and is publicly available on the SEC website and Alvotech investor relations site.
For investor or media inquiries, Alvotech provided contact emails for media and investor relations on its investor site.
Alvotech (NASDAQ: ALVO) published its 2025 Annual Report on March 30, 2026. The report is available in the company's investor relations website and is attached to the announcement in PDF and iXBRL formats. Contact details for media and investors are provided for further inquiries.
Alvotech (NASDAQ: ALVO) reported Q4 2025 revenues of $173M (+13% YoY) and FY 2025 revenues of $593M (+21% YoY). Adjusted EBITDA was $69M in Q4 and $137M for FY 2025 (+27% YoY). Cash on Dec 31, 2025 was $172M. Multiple biosimilar approvals and commercial deals were announced; management reaffirmed 2026 guidance of $650–700M revenue and $180–220M adjusted EBITDA.
Company cited regulatory observations from an FDA inspection and plans to resubmit affected applications in Q2 2026 while expanding partnerships and acquisitions.
Alvotech (NASDAQ: ALVO) will report its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026 after U.S. markets close.
The company will host a conference call with live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). Slides and materials will be posted on the investor website before the call, and registration is required to access the webcast and Q&A.
Alvotech (ALVO) disclosed filings to the Luxembourg CSSF showing a single share transfer within the Aztiq group: 2,701,617 shares were sold and acquired on January 30, 2026 at USD 4.74 per share. The notices reflect an intra‑group transfer between ATP Holdings ehf. and Aztiq Pharma Partners S.à r.l.
Contact provided: Benedikt Stefansson, VP investor relations, valvotech.ir@alvotech.com.
Alvotech (NASDAQ: ALVO) increased share capital by USD 125,000 through issuance of 12,500,000 ordinary shares at USD 5.20 per share to its subsidiary Alvotech Manco ehf.
The subsidiary's holding rises to 16,254,005 shares (4.7%); total issued shares increased from 334,038,147 to 346,538,147. Outstanding shares remain 330,284,142. The increase supports settlement of a prior stock lending facility and the company's obligations for warrants, convertibles, and employee programs.
Alvotech (NASDAQ: ALVO) reported positive top-line results from the pivotal PK study AVT80-GL-P01 comparing AVT80 to Entyvio (vedolizumab). The randomized, double-blind, single-dose, 3-arm study met all primary endpoints for PK similarity and assessed safety, tolerability and immunogenicity in healthy adults.
The company said the study is considered pivotal to support regulatory submissions for both subcutaneous AVT80 and intravenous AVT16. Entyvio global net sales were about US$6.4 billion in 2025.
Alvotech (NASDAQ: ALVO) entered supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada and Australia & New Zealand (announced February 2, 2026). The deals cover one ophthalmology candidate in Canada and three immunology/gastroenterology candidates in Australia/New Zealand.
Sandoz will lead regulatory filings, commercialization and distribution; Alvotech will retain development, global clinical activities and manufacturing and will supply finished product under exclusive supply arrangements.
Alvotech (NASDAQ: ALVO) reached a global licensing and settlement agreement with Regeneron and Bayer resolving all remaining patent disputes for its aflibercept (Eylea) biosimilar. The deal grants worldwide manufacturing and supply rights to Alvotech’s partners and enables staged market entry beginning January 1, 2026.
Market dates include UK and Canada from Jan 1, 2026, Japan limited indications from May 1, 2026, broader Japan indications from Nov 1, 2026, and other countries (excluding U.S.) from May 1, 2026. Remaining terms are confidential.
Alvotech (NYSE:ALVO) disclosed corrected filings to the Luxembourg CSSF reporting manager and closely associated person transactions by ATP Holdings ehf. The filings show an acquisition of 4,812,257 shares on December 17, 2025 and a sale of 2,110,640 shares on December 19, 2025, both at SEK 44.06 per share. The notice corrects an earlier version that mischaracterized the December 19, 2025 transaction. Attachments reference two CSSF filings dated January 5, 2026.